Battaglia, S., Avenanti, A., Vécsei, L., & Tanaka, M. (2024). Neurodegeneration in Cognitive Impairment and Mood Dis-orders for Experimental, Clinical and Translational Neuropsy-chiatry.
Battaglia, S., Avenanti, A., Vécsei, L., & Tanaka, M. (2024). Neurodegeneration in Cognitive Impairment and Mood Dis-orders for Experimental, Clinical and Translational Neuropsy-chiatry.
Battaglia, S., Avenanti, A., Vécsei, L., & Tanaka, M. (2024). Neurodegeneration in Cognitive Impairment and Mood Dis-orders for Experimental, Clinical and Translational Neuropsy-chiatry.
Battaglia, S., Avenanti, A., Vécsei, L., & Tanaka, M. (2024). Neurodegeneration in Cognitive Impairment and Mood Dis-orders for Experimental, Clinical and Translational Neuropsy-chiatry.
Abstract
Neurodegeneration is a major problem in neuroscience and medicine as it causes and worsens many neurological and psychiatric disorders. It involves gradual loss of neurons at different levels of the brain, affecting cognition, emotion, behavior, consciousness, and attention. Understanding the causes and consequences of neurodegeneration is crucial for identifying the risk factors, biomarkers, and treatments. However, the current therapies are mostly symptomatic and ineffective. Therefore, new and innovative methods, such as noninvasive brain stimulation (NIBS), are needed to modulate brain activity and plasticity in a safe and reversible manner. This field is rapidly developing, with a focus on exploring new clinical applications, mechanisms, and combinations of NIBS and drugs. This special issue covers the latest progress and challenges in the study of neurodegeneration in cognitive impairment and mood disorders from the experimental, clinical, and translational perspectives. It addresses the complexity and diversity of these conditions, the lack of disease-modifying treatments, the ethical and practical issues of conducting research in vulnerable and diverse populations, the integration and interpretation of data from multiple sources and modalities, and the development and validation of novel methods such as NIBS, artificial intelligence, and drug repurposing. Collaborative efforts among various stakeholders are needed to improve our knowledge and treatment of neurodegeneration underlying cognitive impairment and mood disorders.
Medicine and Pharmacology, Psychiatry and Mental Health
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
